<DOC>
	<DOCNO>NCT00003052</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Hyperthermia therapy kill tumor cell heat several degree body temperature . It know whether receive chemotherapy plus hyperthermia effective receive chemotherapy alone treat patient soft tissue sarcoma . PURPOSE : This randomized phase III trial study combination chemotherapy alone see well work compare combination chemotherapy hyperthermia therapy treat patient soft tissue sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Hyperthermia Therapy Treating Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine local progression-free survival patient high-risk soft tissue sarcoma treat neoadjuvant etoposide , ifosfamide , doxorubicin without regional hyperthermia . - Determine tumor response rate , local disease control rate , overall survival patient treat regimen . OUTLINE : This randomize study . Patients stratify accord high-risk category ( S1 vs S2 v S3 ) disease site ( extremity vs nonextremity ) . Patients randomize one two treatment arm . - Arm I : Patients receive etoposide IV 30 minute day 1 4 , ifosfamide IV 60 minute day 1-4 , doxorubicin IV 30 minute day 1 . Treatment continue every 21 day total 4 course . Patients also undergo regional hyperthermia . - Arm II : Patients receive chemotherapy alone arm I . Patients arm undergo definitive surgery 4-6 week chemotherapy . Patients also undergo radiotherapy begin 4-6 week surgery . After completion surgery radiotherapy , patient non-resectable tumor show disease progression receive additional 4 course chemotherapy without regional hyperthermia accord treatment schedule . Patients follow every 3 month 1 year , every 4 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 340 patient ( 170 patient per arm ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven grade II III soft tissue sarcoma one follow highrisk group : Grade II/III primary tumor lesion size least 5 cm , deep , extracompartmental ( S1 ) Local recurrence primary tumor ( S2 ) Inadequate surgical excision S1 S2 ( S3 ) Disease recurrence prior surgery allow The following histological type eligible : Malignant fibrous histiocytoma Liposarcoma ( round cell pleomorphic ) Leiomyosarcoma Fibrosarcoma Rhabdomyosarcoma Synovial sarcoma Malignant paraganglioma Neurofibrosarcoma ( malignant schwannoma ) Extraskeletal Ewing 's sarcoma Extraskeletal osteosarcoma Malignant peripheral neuroectodermal tumor Mesenchymal chondrosarcoma Angiosarcoma Miscellaneous sarcoma Unclassified sarcoma No distant metastasis PATIENT CHARACTERISTICS : Age : 18 70 Performance status : WHO 02 OR Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 No bleed disorder Hepatic : Bilirubin le 1.25 time upper limit normal No severe hepatic dysfunction Renal : Creatinine clearance great 60 mL/min No chronic renal failure Cardiovascular : No documented exist cardiac failure No manifest heart failure ( New York Heart Association class III IV ) Left ventricular ejection fraction 10 % institutional normal Other : No prior concurrent malignancy except adequately treat basal cell skin cancer carcinoma situ cervix No severe disease No severe cerebrovascular disease No extremely obese patient No prior metallic implant relevant regional hyperthermia field Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy ( except disease recurrence outside study irradiation field ) Surgery : See Disease Characteristics No prior mutilative surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult extraskeletal osteosarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>stage I adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
</DOC>